Your session is about to expire
← Back to Search
Pembrolizumab for Soft Tissue Sarcoma
Study Summary
This trial will test if doxorubicin and pembrolizumab are safe and effective in treating soft tissue sarcoma.
- Soft Tissue Sarcoma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is this experiment a pioneering endeavor?
"The foundation for researching Pembrolizumab was established in 1997, when Alfacell sponsored the initial clinical trial. After a successful Phase 3 approval process involving 300 patients, 1299 active trials of this drug are ongoing across 71 nations and 3388 cities worldwide."
Has the regulatory agency sanctioned Pembrolizumab for official use?
"Despite the lack of efficacy data, our team gave Pembrolizumab a score of 2 out of 3 due to evidence that it is generally safe."
What is the current enrollment size for this scientific research?
"Unfortunately, this trial is defunct and no longer collecting patients. It was first posted on May 1st 2017, with the final edits occurring on September 29th 2022. However, 443 additional trials for sarcoma are currently enrolling participants and 1299 studies related to Pembrolizumab have open recruitments at present."
Is this clinical investigation open to enrollment currently?
"At the time of writing, this trial is not searching for new participants. It was initially posted on May 1st 2017 and last modified on September 29th 2022. However, there are over four hundred trials seeking enrolment from sarcoma patients and a total of one thousand two hundred ninety-nine studies that focus on pembrolizumab currently recruiting candidates."
What other explorations have been conducted with regards to Pembrolizumab?
"Presently, 1299 active trials are examining the efficacy of Pembrolizumab with 236 being in Phase 3. The primary concentration for these studies is Houston, Texas; nevertheless, there are 58237 total sites conducting research on this drug."
What afflictions has Pembrolizumab been demonstrated to alleviate?
"Pembrolizumab is a widely accepted therapy for unresectable melanoma. It has also been clinically shown to treat microsatellite instability high, neuroblastoma (nb), and cases with an elevated risk of relapse."
Share this study with friends
Copy Link
Messenger